Modelling the Impact of Antibiotic Use on Antibiotic-resistant Escherichia Coli Using Population-based Data from a Large Hospital and Its Surrounding Community
Overview
Authors
Affiliations
Objectives: To determine the temporal relationship between antibiotic use and incidence of antibiotic-resistant Escherichia coli in both the inpatient and outpatient setting of a large urban area.
Methods: A retrospective observational time-series analysis was performed to evaluate the incidence of non-duplicate clinical isolates of E. coli resistant to ciprofloxacin, trimethoprim/sulfamethoxazole and cefepime from January 2000 through December 2007, combined with a transfer function model of aggregated data on antibiotic use in both settings obtained from the hospital's pharmacy and outpatient billing offices.
Results: Ciprofloxacin resistance increased from 6.0% (2000) to 15.4% (2007; P<0.0001) and cefepime resistance from 0.9% (2002) to 3.2% (2007; P=0.01). Trimethoprim/sulfamethoxazole resistance remained stable (23.7%-25.8%). Total antibiotic use increased in both settings, while fluoroquinolone use increased significantly only among outpatients. A temporal effect between fluoroquinolone resistance in community E. coli isolates and outpatient use of ciprofloxacin (immediate effect and time lag 1 month) and moxifloxacin (time lag 4 months) was observed, explaining 51% of the variance over time. The incidence of cefepime resistance in E. coli was correlated with ciprofloxacin use in the inpatient (lag 1 month) and outpatient (lag 4 months) settings and with the use of ceftriaxone (lag 0 month), piperacillin/tazobactam (3 months) and cefepime (3 months) in the hospital (R2=51%).
Conclusions: These results support efforts to reduce prescribing of fluoroquinolones for control of resistant E. coli including extended-spectrum β-lactamase producers and show the added value of time-series analysis to better understand the interaction between community and hospital antibiotic prescribing and its spill-over effect on antibiotic resistance.
Martinez E, Verbon A, Schoffelen A, Altorf-van der Kuil W, van Rosmalen J Lancet Reg Health Eur. 2025; 50():101197.
PMID: 39850254 PMC: 11755011. DOI: 10.1016/j.lanepe.2024.101197.
Lin G, Poleon S, Hamilton A, Salvekar N, Jara M, Haghpanah F One Health. 2025; 20():100951.
PMID: 39816238 PMC: 11733049. DOI: 10.1016/j.onehlt.2024.100951.
Gorgulho A, Cunha F, Alves Branco E, Azevedo A, Almeida F, Duro R Antibiotics (Basel). 2023; 12(2).
PMID: 36830199 PMC: 9952766. DOI: 10.3390/antibiotics12020288.
Alnajjar M, Jawhar D, Aburuz S, Saeed D, Ibrahim A Pharm Pract (Granada). 2023; 20(3):2685.
PMID: 36733515 PMC: 9851827. DOI: 10.18549/PharmPract.2022.3.2685.
Poku E, Cooper K, Cantrell A, Harnan S, Abu Sin M, Zanuzdana A JAC Antimicrob Resist. 2023; 5(1):dlad001.
PMID: 36694849 PMC: 9856344. DOI: 10.1093/jacamr/dlad001.